Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Astrazeneca (AZNCF) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Astrazeneca (AZNCF) over the last 16 years, with Q4 2025 value amounting to 19.21%.

  • Astrazeneca's EBIT Margin rose 55400.0% to 19.21% in Q4 2025 from the same period last year, while for Dec 2025 it was 23.4%, marking a year-over-year increase of 49000.0%. This contributed to the annual value of 23.4% for FY2025, which is 49000.0% up from last year.
  • As of Q4 2025, Astrazeneca's EBIT Margin stood at 19.21%, which was up 55400.0% from 23.59% recorded in Q3 2025.
  • Over the past 5 years, Astrazeneca's EBIT Margin peaked at 699.44% during Q3 2022, and registered a low of 16.97% during Q3 2021.
  • In the last 5 years, Astrazeneca's EBIT Margin had a median value of 21.37% in 2023 and averaged 99.93%.
  • Its EBIT Margin has fluctuated over the past 5 years, first surged by 7164100bps in 2022, then tumbled by -6824400bps in 2023.
  • Quarter analysis of 5 years shows Astrazeneca's EBIT Margin stood at 2.43% in 2021, then soared by 28581bps to 692.41% in 2022, then tumbled by -99bps to 10.26% in 2023, then soared by 33bps to 13.67% in 2024, then soared by 40bps to 19.21% in 2025.
  • Its EBIT Margin stands at 19.21% for Q4 2025, versus 23.59% for Q3 2025 and 24.27% for Q2 2025.